{"id":616448,"date":"2022-09-15T16:18:01","date_gmt":"2022-09-15T16:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=616448"},"modified":"2022-09-15T16:18:01","modified_gmt":"2022-09-15T16:18:01","slug":"liver-fibrosis-market-to-witness-upsurge-in-growth-during-the-forecast-period-20222032-examines-delveinsight-key-companies-inventiva-pharma-galmed-research-and-development-ltd","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/liver-fibrosis-market-to-witness-upsurge-in-growth-during-the-forecast-period-20222032-examines-delveinsight-key-companies-inventiva-pharma-galmed-research-and-development-ltd_616448.html","title":{"rendered":"Liver Fibrosis Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies &#8211; Inventiva Pharma, Galmed Research and Development, Ltd."},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1663245135.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Liver Fibrosis Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies - Inventiva Pharma, Galmed Research and Development, Ltd.\" src=\"https:\/\/www.abnewswire.com\/uploads\/1663245135.jpeg\" alt=\"Liver Fibrosis Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies - Inventiva Pharma, Galmed Research and Development, Ltd.\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cLiver Fibrosis Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of Liver Fibrosis, historical and forecasted epidemiology as well as the Liver Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">The<strong> <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/liver-fibrosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Liver Fibrosis market<\/a> <\/strong>is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Liver Fibrosis pipeline products will significantly revolutionize the Liver Fibrosis market dynamics.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Liver Fibrosis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Liver fibrosis is caused by the accumulation of extracellular matrix (ECM) proteins, mostly collagens Type I and Type III, followed by the formation of fibrous scar, which can ultimately compromise normal liver function. Advanced liver fibrosis results in cirrhosis, liver failure, and portal hypertension and often requires liver transplantation.<\/p>\n<p style=\"text-align: justify;\">Liver fibrosis diagnosis cannot be made in its mild to moderate stages, and this is because liver fibrosis does not usually cause symptoms until more of the liver is damaged. While progressing towards liver disease, the patient may experience symptoms including appetite loss, fluid buildup in the legs or stomach, jaundice, nausea, unexplained weight loss, and many others<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Liver Fibrosis Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Liver Fibrosis market size was estimated at <strong>USD 2,225 Million<\/strong> in the year 2021 and is anticipated to grow with a significant <strong>CAGR<\/strong> during the study period <strong>(2019-2032)&nbsp;<\/strong><\/li>\n<li>In 2021, nearly <strong>19,126,579<\/strong> Diagnosed Prevalent Cases of Liver Fibrosis occurred in the 7MM&nbsp;<\/li>\n<li>The United States presented the highest Diagnosed Prevalent Cases of Liver Fibrosis in2021around 9,488,135 cases&nbsp;<\/li>\n<li>Among the European countries, Germany had the highest Diagnosed Prevalent Cases of Liver Fibrosis with <strong>1,641,162<\/strong> cases, followed by Italy with <strong>1,532,651<\/strong> cases in 2021&nbsp;<\/li>\n<li><strong>Key Liver Fibrosis Companies:<\/strong> Inventiva Pharma, Galmed Research and Development, Ltd, Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, 89bio, Inc., ZydusTherapeutics, Axcella, Rivus Pharmaceuticals, Inc., Lipocine Inc., Novo Nordisk, HighTide Biopharma, Akero Therapeutics, Inc, Enyo Pharma, Sagimet Biosciences Inc, and others&nbsp;<\/li>\n<li><strong>Key Liver Fibrosis Therapies:<\/strong> Lanifibranor, Aramchol, MGL-3196, Obeticholic acid, Pegozafermin, Saroglitazar Magnesium, AXA1125, HU6, LPCN 1144, Semaglutide, HTD1801 , Efruxifermin, Vonafexor, TVB-2640, and others&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/liver-fibrosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Liver Fibrosis Market Report<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key benefits of the Liver Fibrosis Market report:<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Liver Fibrosis market report covers a descriptive overview and comprehensive insight of the Liver Fibrosis Epidemiology and Liver Fibrosis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Liver Fibrosis market report provides insights on the current and emerging therapies.<\/li>\n<li>Liver Fibrosis market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Liver Fibrosis market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Liver Fibrosis market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Liver Fibrosis market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/liver-fibrosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Liver Fibrosis market forecast<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Liver Fibrosis Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Liver Fibrosis market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Liver Fibrosis<\/li>\n<li>Prevalent Cases of Liver Fibrosis by severity<\/li>\n<li>Gender-specific Prevalence of Liver Fibrosis<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Liver Fibrosis&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Liver Fibrosis Market &nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The dynamics of the Liver Fibrosis market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as <strong>Aramchol, MGL-3196,<\/strong> and others during the forecasted period 2019-2032.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Liver Fibrosis epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/liver-fibrosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Liver Fibrosis Epidemiological Insights<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Liver Fibrosis Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Rich emerging pipeline<\/li>\n<li>Understanding of pathophysiology<\/li>\n<li>Increased awareness<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Liver Fibrosis Therapies and Key Companies&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Lanifibranor:<\/strong> Inventiva Pharma<\/li>\n<li><strong>Aramchol:<\/strong> Galmed Research and Development, Ltd<\/li>\n<li><strong>MGL-3196:<\/strong> Madrigal Pharmaceuticals, Inc.<\/li>\n<li><strong>Obeticholic acid:<\/strong> Intercept Pharmaceuticals<\/li>\n<li><strong>Pegozafermin:<\/strong> 89bio Inc.<\/li>\n<li><strong>Saroglitazar Magnesium:<\/strong> ZydusTherapeutics<\/li>\n<li><strong>AXA1125:<\/strong> Axcella<\/li>\n<li><strong>HU6:<\/strong> Rivus Pharmaceuticals, Inc.<\/li>\n<li><strong>LPCN 1144:<\/strong> Lipocine Inc.<\/li>\n<li><strong>Semaglutide:<\/strong> Novo Nordisk<\/li>\n<li><strong>HTD1801:<\/strong> HighTide Biopharma<\/li>\n<li><strong>Efruxifermin:<\/strong> Akero Therapeutics, Inc<\/li>\n<li><strong>Vonafexor:<\/strong> Enyo Pharma<\/li>\n<li><strong>TVB-2640:<\/strong> Sagimet Biosciences Inc&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Liver Fibrosis Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Liver Fibrosis Companies:<\/strong> Inventiva Pharma, Galmed Research and Development, Ltd, Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, 89bio, Inc., ZydusTherapeutics, Axcella, Rivus Pharmaceuticals, Inc., Lipocine Inc., Novo Nordisk, HighTide Biopharma, Akero Therapeutics, Inc, Enyo Pharma, Sagimet Biosciences Inc, and others<\/li>\n<li><strong>Key Liver Fibrosis Therapies:<\/strong> Lanifibranor, Aramchol, MGL-3196, Obeticholic acid, Pegozafermin, Saroglitazar Magnesium, AXA1125, HU6, LPCN 1144, Semaglutide, HTD1801 , Efruxifermin, Vonafexor, TVB-2640, and others<\/li>\n<li><strong>Liver Fibrosis Therapeutic Assessment:<\/strong>&nbsp; Liver Fibrosis current marketed and Liver Fibrosis emerging therapies<\/li>\n<li><strong>Liver Fibrosis Market Dynamics:<\/strong>&nbsp;Liver Fibrosis market drivers and barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Liver Fibrosis&nbsp; Market Access and Reimbursement<\/strong>&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Liver Fibrosis Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>No standard treatment<\/li>\n<li>Insufficient delivery of anti-fibrotic drugs<\/li>\n<li>High economic burden<\/li>\n<li>Complex mechanisms<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Liver Fibrosis Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Liver Fibrosis<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Liver Fibrosis<\/p>\n<p style=\"text-align: justify;\">4. Liver Fibrosis Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Liver Fibrosis Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Liver Fibrosis Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Liver Fibrosis Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Liver Fibrosis&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Liver Fibrosis Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Liver Fibrosis Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Liver Fibrosis Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Liver Fibrosis Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Liver Fibrosis Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Liver Fibrosis Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Liver Fibrosis Market drivers<\/p>\n<p style=\"text-align: justify;\">16. Liver Fibrosis Market barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Liver Fibrosis Appendix<\/p>\n<p style=\"text-align: justify;\">18. Liver Fibrosis Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Liver Fibrosis treatment, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/liver-fibrosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Liver Fibrosis Medications<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=liver-fibrosis-market-to-witness-upsurge-in-growth-during-the-forecast-period-20222032-examines-delveinsight-key-companies-inventiva-pharma-galmed-research-and-development-ltd\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=liver-fibrosis-market-to-witness-upsurge-in-growth-during-the-forecast-period-20222032-examines-delveinsight-key-companies-inventiva-pharma-galmed-research-and-development-ltd\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight\u2019s \u201cLiver Fibrosis Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of Liver Fibrosis, historical and forecasted epidemiology as well as the Liver Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/liver-fibrosis-market-to-witness-upsurge-in-growth-during-the-forecast-period-20222032-examines-delveinsight-key-companies-inventiva-pharma-galmed-research-and-development-ltd_616448.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[447,405,417,406,423],"tags":[],"class_list":["post-616448","post","type-post","status-publish","format-standard","hentry","category-Education","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/616448","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=616448"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/616448\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=616448"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=616448"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=616448"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}